A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
Latest Information Update: 13 Oct 2024
At a glance
- Drugs NP-001 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Neuraltus Pharmaceuticals
- 07 Oct 2024 According to a Neuvivo media release, company announced it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for NP001 (sodium chlorite infusion) to treat amyotrophic lateral sclerosis (ALS). This submission was based on the evidence shown in this phase 2b and other studies.
- 01 Feb 2022 According to a Neuraltus Pharmaceuticals, Merit Cudkowicz, M.D is the investigator of phase 2 studies.
- 01 Feb 2022 According to a Neuraltus Pharmaceuticals media release, data from this trial was published in in Peer-Reviewed Journal, Muscle & Nerve.